Peripartum cardiomyopathy has a better prognosis than other forms of nonischemic cardiomyopathy, with rare need for advanced therapies like implantable defibrillators or cardiac transplant.
Peripartum cardiomyopathy (PPCM) is a well-established complication of pregnancy. Criteria include heart failure that presents with reduced left ventricular function, signs and symptoms of heart failure either late in pregnancy or early in the postpartum period. The incidence varies widely depending geography and ethnicity. The pathophysiology of PPCM is still an area of active investigation, but includes immune and inflammatory mechanisms, which are the subject of several investigations. Therapies for chronic heart failure from PPCM are similar to those patients with nonischemic cardiomyopathy from different etiologies, however novel therapies may include bromocriptine, pentoxifylline or other potential therapies influencing the immune system. The need for implantable defibrillators, left ventricular assist devices and cardiac transplant in women with PPCM is rare, and prognosis is better than other forms of nonischemic cardiomyopathy. Despite this, further information about the epidemiology, prognosis and potential therapies are required to better manage and diagnose PPCM in women with signs and symptoms of heart failure.
Sheppard et al. (Thu,) conducted a review in Peripartum cardiomyopathy. Peripartum cardiomyopathy has a better prognosis than other forms of nonischemic cardiomyopathy, with rare need for advanced therapies like implantable defibrillators or cardiac transplant.